VCM
RNA

Versant Capital Management’s Atrium Therapeutics RNA Stock Holding History

Versant Capital Management’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.56K Buy
+265
New +$3.46K ﹤0.01% 2496

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

Versant Capital Management's RNA Position: Q2 2026 in Review

Versant Capital Management opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 265 shares worth $3.56K. The stake represents ﹤0.01% of the portfolio and ranks #2496 among its holdings.

8 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Versant Capital Management held 265 shares of Atrium Therapeutics worth $3.56K as of Q2 2026.
  • Atrium Therapeutics was a new Versant Capital Management position in Q2 2026.
  • Atrium Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2496 holding.
  • 8 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.